Prognostics Factor | Subgroups | Value for prognostic score |
---|---|---|
Independent Factors | ||
Patient Age | >60Â years | 1 |
 | 50–60 years | 2 |
 | <50 years | 3 |
KPS | <50% | 1 |
 | 50–70% | 2 |
 | >70% | 3 |
Histology | WHO Grade IV | 1 |
 | WHO Grade III | 2 |
 | WHO Grade II | 3 |
Presence of symptoms | Documented neurological symptoms related to recurrence requiring steroid management | 1 |
 | Documented neurologicalsymptoms relatedto recurrence or impending neuro symptoms | 2 |
 | No neurological symptoms related to recurrence | 3 |
Target Control | ||
Tumor size (GTV) | >500Â cm3 or diffuse disease/ gliomatosis | 1 |
 | 20–500 cm3 | 2 |
 | <20 cm3 | 3 |
Tumor recurrencelocation withrespect to originaltreatment field (60Gy isodose line) | <1Â cm away or completelywithin the original treatment field | 1 |
 | 1–3 cm away | 2 |
 | >3 cm away | 3 |
Diffuse disease present | Multiple T1 gadolinium- enhancing lesions | 1 |
 | T2 FLAIR diffuse involvement | 2 |
 | None (localized recurrence only) | 3 |
Anticipated Toxicity Risk | ||
OAR location with respect to recurrence area | >1Â cm away from or in the recurrence area | 1 |
 | 1–3 cm away from recurrence area | 2 |
 | >3 cm away from the recurrence area | 3 |
OAR dose contribution from original treatmenta | <90% dose allowed as per Quantec dose constraints | 1 |
 | Within +/− 10% of dose allowed as per Quantec constraints | 2 |
 | Exceeds >10% over the Quantec constraints | 3 |
Disease free interval from initial treatment with radiation | <1Â year | 1 |
 | 1–3 years | 2 |
 | >3 years | 3 |